ZETADISPLAY AB (publ) INTERIM REPORT 1 APRIL 30 JUNE 2025 (Q2)
Q2 Interim report April – June 2025 for ZetaDisplay AB (publ) is…
Zelluna ASA Reports Second Quarter 2025 Financial Results and Provides General Business Update
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering…
Galapagos NV Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to GLPG5101 for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Mechelen, Belgium; August 6, 2025, 7:30 CET; regulated information – inside information…
ASM announces completion of share buyback program
Almere, The NetherlandsJuly 28, 2025, 5:45 p.m. CET ASM International N.V. (Euronext…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron…
Equasens: availability of AGM preparatory materials
Villers-lès-Nancy, 6 June 2025 - 6:00 p.m. (CET) PRESS RELEASE ANNUAL ORDINARY…
Maxim Group initiates the coverage of the CROSSJECT share with a BUY recommendation and a target price of 4.00
Press release Maxim Group initiates the coverage of the CROSSJECT share with…